Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Wilson

Showing results (51-60 of 125) with videos related to

Pageof 13
Sort By:
Cancer Chemotherapy and Pharmacology|December 24, 2002
Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)Bronwyn G Siim, Alan E Lee, Sahar Shalal-Zwain, et al.
Plos Computational Biology|October 26, 2018
An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroidsXinjian Mao, Sarah McManaway, Jagdish K Jaiswal, et al.
Radiation Research|May 26, 2007
Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustardsWilliam R Wilson, Kevin O Hicks, Susan M Pullen, et al.
BMC Cancer|October 11, 2011
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patientsMark J McKeage, Yongchuan Gu, William R Wilson, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2007
Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamineKevin O Hicks, Hilary Myint, Adam V Patterson, et al.
RSC Medicinal Chemistry|July 24, 2023
Hypoxia-activated prodrugs of phenolic olaparib analogues for tumour-selective chemosensitisationWay W Wong, Sophia F O'Brien-Gortner, Robert F Anderson, et al.
Bioorganic & Medicinal Chemistry|July 20, 2011
The effect of sulfonate leaving groups on the hypoxia-selective toxicity of nitro analogs of the duocarmycinsAmir Ashoorzadeh, Graham J Atwell, Frederik B Pruijn, et al.
The Journal of Biological Chemistry|November 8, 2013
Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependenceJiechuang Su, Yongchuan Gu, Frederik B Pruijn, et al.
Journal of Medicinal Chemistry|February 18, 2005
Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer culturesFrederik B Pruijn, Joanna R Sturman, H D Sarath Liyanage, et al.
Frontiers in Oncology|October 11, 2013
The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104Annika Foehrenbacher, Kashyap Patel, Maria R Abbattista, et al.
Pageof 13

Showing results (51-60 of 125) with videos related to

Sort By:
Pageof 13
Cancer Chemotherapy and Pharmacology|December 24, 2002
Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)Bronwyn G Siim, Alan E Lee, Sahar Shalal-Zwain, et al.
Plos Computational Biology|October 26, 2018
An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroidsXinjian Mao, Sarah McManaway, Jagdish K Jaiswal, et al.
Radiation Research|May 26, 2007
Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustardsWilliam R Wilson, Kevin O Hicks, Susan M Pullen, et al.
BMC Cancer|October 11, 2011
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patientsMark J McKeage, Yongchuan Gu, William R Wilson, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2007
Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamineKevin O Hicks, Hilary Myint, Adam V Patterson, et al.
RSC Medicinal Chemistry|July 24, 2023
Hypoxia-activated prodrugs of phenolic olaparib analogues for tumour-selective chemosensitisationWay W Wong, Sophia F O'Brien-Gortner, Robert F Anderson, et al.
Bioorganic & Medicinal Chemistry|July 20, 2011
The effect of sulfonate leaving groups on the hypoxia-selective toxicity of nitro analogs of the duocarmycinsAmir Ashoorzadeh, Graham J Atwell, Frederik B Pruijn, et al.
The Journal of Biological Chemistry|November 8, 2013
Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependenceJiechuang Su, Yongchuan Gu, Frederik B Pruijn, et al.
Journal of Medicinal Chemistry|February 18, 2005
Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer culturesFrederik B Pruijn, Joanna R Sturman, H D Sarath Liyanage, et al.
Frontiers in Oncology|October 11, 2013
The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104Annika Foehrenbacher, Kashyap Patel, Maria R Abbattista, et al.
Pageof 13